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Pharmacogenetics

The Effect of CYP3A5 Polymorphism on
Kidney Transplant Recipients Given Tacrolimus
Samia Alam, Sunitha Johns, Haval Norman, Brian Heilbronner, YousifRojeab, BS, Ph.D.

Abstract
Tacrolimus, an immunosuppressant agent indicated for organ transplants, is commonly administered to reduce the risk
of renal graft rejection in patients with chronic kidney disease (CKD) and end stage renal disease (ESRD). Due to its
narrow therapeutic index and high inter-patient variability,
studies have suggested that CYP3A5-based dosing provides
specialized regimens which may significantly improve the
chances of achieving therapeutic concentrations. According
to the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations, extensive (CYP3A5*1/*1) and
intermediate metabolizers (CYP3A5*1/*3) require a higher
initial dose while poor metabolizers (CYP3A5*3/*3) require
a lower initial dose in order to achieve target tacrolimus concentrations. Studies concluded that CYP3A5 expressers present a greater risk for chronic nephrotoxicity and acute
transplant rejection, supporting the need to closely monitor
patients for severe adverse events. Further trials considering
CYP3AS polymorphisms are needed to determine whether
this genotype dosing improves clinical outcomes, which includes reducing rejection and toxicity, before testing can be
recommended.
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Introduction
According to the Centers for Disease Control and Prevention
(CDC), chronic kidney disease (CKD) is a top 10 cause of mortality in the United States, and approximately 20 million
American adults have some level of CKD. 1 While the prevalence of CKD is highest in patients older than 60 years
(24.5%), CKD is burdensome and costly to patients,
healthcare providers and payers.2 Chronic kidney disease can
potentially progress to end stage renal disease (ESRD),
resulting in irreversible kidney damage with significantly
impaired ability to properly regulate fluid balance, waste
excretion, acid-base chemistry, blood pressure and other
metabolic functions. According to the 2014 United States
Renal Data System annual data report, in 2012 there were
636,905 prevalent cases of ESRD in the United States, which
includes 114,813 new cases. The highest rates of ESRD occurred in populations greater than 45 years old and in the
Ohio/Mississippi Valley.
Currently, there are three treatment options available for
patients with ESRD: hemodialysis (HD), peritoneal dialysis
(PD) or kidney transplant. Among patients with ESRD in the
United States, 402,514 utilize HD, 40,605 utilize PD and
175,978 have a functioning renal graft.2 In 2012, there were
17,305 kidney transplants performed, marking a 2 percent
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decline from 2011.Although the majority of organs came
from deceased donors (11,535), live donors were preferred
due to increased post-transplantation functionality and longer survival rates. By the end of 2012, there were 81,982 patients on the waiting list to receive a transplant, with 46,693
classified as status la (urgent), lb (stable on medical device)
or 2 (stable on oral medications). The remaining patients
were classified as status 7 (inactive due to change in condition).
Unfortunately, the demand for kidneys is 2. 7 times higher
than the supply with an average patient wait time of five
years before receiving a kidney. Patients aged 17 years and
younger in need of a transplant are most likely to receive a
kidney while patients aged 65 to 74 years are least likely
based on the Organ Procurement and Transplantation Network Policies. As with many solid organ transplantation procedures, a major concern for kidney transplant is host rejection of the graft. The advent of the immunosuppressive calcineurin inhibitor (CNI) class, consisting of cyclosporine and
tacrolimus, helped revolutionize organ transplantation therapeutics by reducing host rejection, thereby cutting the cost
of treating a rejection and allowing hospitals to perform
transplants at higher rates. Because of these immunosuppressive agents, there is only a 7 to 9 percent chance that an
acute rejection will occur. These agents also reduced longterm graft failure rates to 7.7 percent, with only 3.7 percent
of those failures resulting in fatality.
Cyclosporine was previously the drug of first choice, but it
has since been replaced by tacrolimus which is now used to
treat 91.8 percent of patients receiving a transplant because
of its greater potencyPWhile tacrolimus is considered highly efficacious, recent studies suggest that tacrolimus levels
may have inter-patient variability based on previously unknown pharmacogenetic influences on drug metabolism.
This could potentially alter current renal transplant treatment guidelines for tacrolimus in terms of genetic testing
and dosing.

Tacrolimus
Pharmacokinetics
Tacrolimus is a macrolide isolated from Streptomyces tsukubaesis that binds to FK506 binding proteins (FKBP12 and
FKBP52) on the glucocorticoid receptor complex.4 Once
bound to the FK506 proteins, the complex binds to the
calcium/calmodulin dependent phosphatase, calcineurin.
Without active calcineurin, T cell transduction signaling is
inhibited because nuclear translocation does not occur,
disallowing cytokine gene transcription. The cytokines inhibited are interleukin 2, interferon gamma and tumor necrosis
factor alpha.
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Tacrolimus has a bioavailability of about 25 percent, but may
range from 5 to 93 percent, reaching its peak concentration
in 30 minutes to one hour.s Decreased bioavailability is
attributed to poor gut motility or poor solubility in the
gut, therefore, oral doses must be three to four times greater
than that of intravenous solutions to reach equivalent
serum levels. African-Americans and non-Cau casian populations achieve lower bioavailability, possibly due to genetic
variations in metabolism.6 Once absorbed, tacrolimus binds
extensively to red bloods cells which helps protect the drug
from hepatic metabolism.? In the intestines and liver,
CYP3A4 and CYP3AS enzymes metabolize tacrolimus by
o-demethylation, hydroxylation and oxidation.s After
metabolism, 95 percent is excreted via the biliary route and
2.5 percent is excreted in the urine.9
For the prophylactic treatment of renal graft rejection following kidney transplantation, the standard dose is 0.1 to 0.2
mg/kg/day divided into two doses taken every 12 hours.10
Guidelines also suggest a target trough concentration of 15 to
20 ng/ml be evaluated daily once steady-state has been
reached post transplantation until hospital discharge, as tacrolimus causes nephrotoxicity in SO percent of patients.10,11
Tacrolimus levels can then be titrated to desired levels based
on tolerability and clinical outcomes. Pediatric and AfricanAmerican patients often need two to four times higher doses
of tacrolimus to maintain therapeutic trough levels compared to other populations because of genetic and metabolic
variations.12 Even though tacrolimus therapy alone can cause
nephrotoxicity, it is difficult to determine whether the incidence of nephrotoxicity is caused by tacrolimus therapy,
comorbid medical conditions or drug interactions.13 Because
of the high inter-patient variability in bioavailability and potential risk of nephrotoxicity, determining the right dose of
tacrolimus is essential to graft survival. Recent studies reveal
a genetic element to dosing that has helped patients achieve a
therapeutic level of tacrolimus more consistently than before.
Pharmacogenetics
Evidence suggests that initial dosing of tacrolimus should be
dependent on the CYP3AS genotype instead of an entirely
weight-based dosing regimen.14 In a 2010 study conducted
by Zhang et al., Chinese renal transplant patients who received tacrolimus based on genotype efficiently achieved
therapeutic concentrations in the blood in a shorter time.
Within the CYP3AS*l/*3 genotype group, 46.7 percent of
patients achieved the therapeutic range of 6 to 12 ng/ml
when standard tacrolimus weight-based dosing of 0.1 mg/kg
was initially administered post-transplant. However, 46.7
percent of CYP3AS*l/*3 patients had blood concentrations
that were below therapeutic range, indicating that a higher
dose was needed (P=l.000). When dosing was determined
by genotype, 81.8 percent of CYP3AS*l/*3 patients were in
therapeutic range while only 9.1 percent of CYP3AS*l/*3
were below therapeutic range (P=0.674). It is evident that
dose adjustments based on genotype decreased the number
of patients that were outside the therapeutic range and increased the number of patients that were within range
(Table 1). Administration of the initial 0.1 mg/kg in
CYP3A5*3 /*3 patients led to a greater percentage of patients

24

who had tacrolimus blood concentrations exceeding the therapeutic range; however, the percentage of patients outside
the range significantly decreased once dosing was determined by genotype (46.2% P=0.021versus 11.5% P=l.000) .
Table 1. Tacrolimus blood concentrations of CYP3A5*1/
*3 patients on weight-based and genotype-based dosing
regimens.1 4

Subtherapeutic
(< 6 ng/ml)

Therapeutic
(6-12 ng/ml)

Weight-based
dosing

46.7% (7 /15)

46. 7% (7 /15)

Genotype-based
dosing

9.1% (2/22)

81.8% (18/22)

Tacrolimus blood concentrations were measured on the
third day after kidney transplant. The weight-based dosing
group consisted of Chinese adults (median age 33.5 years)
who received 0.1 mg/kg/day. The genotype-based dosing
group consisted of Chinese adults (median age 32 years) who
received 0.15 mg/kg/day based on their CYP3AS*l/*3 genotype. When dosing was based on genotype, the percentage of
patients having subtherapeutic levels decreased, and the percentage of patients having therapeutic levels increased supporting the use of genotype-based dosing for tacrolimus.
The prevalence of tacrolimus toxicity among the different
CYP3AS variants is still being studied (Table 2).15 A metaanalysis performed by Rojas et al., concluded that CYP3AS
expressers (CYP3AS*l/*1 and CYP3A5*1/*3) present a
greater risk for chronic nephrotoxicity (OR=2.42, 95% CI
1.51-3.90, 12=0%), and a greater risk for acute transplant
Table 2. Risk of adverse events between CYP3A5 expressers and non-expressers.1s

Chronic
nephrotoxicity

Arute transplant
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rejection

Odds
Ratio
(OR)

95%
Confidence
Interval (Cl)

Heterogeneity
(12)

2.42

1.51-3.90

0%

1.32

1.02-1.71

3%
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rejection (OR=l.32, 95% CI 1.02-1.71, 12=3%) than CYP3A5
non-expressers (CYP3AS*3/*3). Furthermore, the use of tacrolimus results in neurotoxic effects such as tremor, headaches, and insomnia, in addition to its known nephrotoxic
effects. 16
A systematic review and meta-analysis analyzed five studies
for chronic nephrotoxicity (n=867), excluding one study in
the post hoc sensitivity analysis, and 21 studies for acute
transplant rejection (n=2185). The CYP3A5 expressers included patients with CYP3A5*1/*1 and CYP3AS*l/*3 genotype. The CYP3A5 non-expressers included patients with
CYP3A5 *3/*3 genotype. The elevated odds ratio indicated
that patients had a higher ri sk of chronic nephrotoxicity and
acute transplant rejection.

In a study conducted by Tholking et al., the tacrolimus
metabolism rate expressed as the blood concentration
normalized by the dose (C/D ratio) was used as a predictor
to identify at risk patients for developing CNI toxicity: 11

C/D ratio (ng/mL * 1/mg) =blood tacrolimus trough level
(ng/ml)/daily tacro/imus dose (mg)
In this study, renal function was analyzed one, two, three, six,
12 and 24 months after renal transplantation in patients prescribed tacrolimus. The patients were divided into three
groups: fast (CYP3A5*1/*l), moderate (CYP3A5*1/*3) and
slow metabolizers (CYP3A5*3/*3). Fast metabolizers of
tacrolimus had a C/D ratio <l.05 ng/mL *1/mg while slow
metabolizers had a C/D ratio of <!l.55 ng/mL *1/mg. Intermediate metabolizers typically had a mean C/D ratio value of
1.05 to 1.54 ng/mL *1/mg. Fast metabolizers had lower estimated glomerular filtration rates ( eGFR) at all time points
when compared with slow metabolizers. At the 24-month
point, fast metabolizers versus slow metabolizers had a
change in mean eGFR (ml/min/1.73 m2) of -8.8 with a 95
percent confidence interval from -14.7 to -2.8 (p=0.0039).
Also, patients classified as fast metabolizers were shown to
have lower renal function and a higher mortality within two
years (mortality rates: fast 7.4% versus intermediate 4.4%
versus slow 4.9%). In addition, 5 percent of the fast metabolizers died from infections, which was a common reason for
mortality, while none occurred in slow metabolizers
(p=0.111). Fast metabolizers also had a higher incidence of
CNI nephrotoxicity (p=0.015). In this study, 9 percent of fast
metabolizers switched therapy from tacrolimus due to CNI
toxicity, while only 1 percent of slow metabolizer switched
(p=0.047). The mean daily dose (mg) oftacrolimus required
was higher in fast metabolizers than that in the intermediate
and slow metabolizers (11 mg (range: 6.3-26.7), 7.5 mg
(range: 4-14) and 5.5 mg (range: 2.33-11.5) respectively)
(p<0.001). Thus, genotyping for the CYP3A5 gene is not only
helpful in predicting response to tacrolimus, but also is a valuable predictor of adverse events.
Furthermore, the polymorphism of CYP3A5 explains not only
the wide variability of the drug's pharmacokinetics but also
its interaction with other medications such as diltiazem. A
patient's CYP3A5 genotype can possibly be used to predict
Winter 2016 Volume
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whether tacrolimus can be co-administered with such
medications in an individual patient A randomized, parallelcontrolled study completed in Chinese renal transplant
patients in 2013 by Chen et al., reported that the tacrolimus
dose necessary to reach the target level trough concentration
(CO), which is comparable to a Css, min, is associated with the
CYP3A5 genotype.is Expressers of CYP3AS (CYP3AS*l/*1
and *1/*3) needed higher doses of tacrolimus than CYP3A5
non-expressers (CYP3A5*3/*3) to reach a comparable CO
level. It was also found that when diltiazem was not used
with tacrolimus, CYP3A5 expressers required a significantly
higher dose of tacrolimus to reach a target CO level as seen in
the day 14 post-transplant analysis between the expresser
group that received diltiazem and the expresser group without diltiazem, 0.06 mg/kg± 0.01 mg/kg versus 0.09 mg/kg ±
0.02 mg/kg (p= 0.017), respectively. Diltiazem could reduce
tacrolimus dose in the CYP3A5 non-expressers as seen in the
day 14 post-transplant analysis between the non-expresser
group that received diltiazem versus the non-expresser
group that did not receive diltiazem, although the dose was
not significantly reduced (0.05 mg/kg ± 0.01 mg/kg versus
0.09 mg/kg± 0.06 mg/kg, respectively) (p= 0.017). Thus, the
results suggest that a single nucleotide polymorphism in
CYP3AS can change the metabolic interaction between tacrolimus and diltiazem. More specifically, the results show that
diltiazem can act as a tacrolimus-saving agent in CYP3A5
expressers.
There are demonstrated potential benefits for CYP3A5
genotype testing, but evidence is inconclusive whether genotype-based dosing is superior to standard therapeutic drug
monitoring at achieving clinical end points. A 2010 study by
Thervet and colleagues found genotype dosing had significantly lower time needed to achieve target tacrolimus
concentrations (p=0.001) and fewer dose adaptations
compared to therapeutic drug monitoring (p=0.004).19 However, there was no difference between treatment groups in
delayed graft function, acute rejection, occurrence of tacrolimus-related nephrotoxicity or renal function . The study
design introduced tacrolimus seven days post-transplant
following biological therapy with either basiliximab or rabbit
thymocyte antiglobulin; the authors acknowledged that clinical outcome effects may be more significant when tacrolimus
is initiated on the day of transplant.
Clinical Applications
The Clinical Pharmacogenetics Implementation Consortium
(CPIC) is neither for nor against CYP3A5 genotype testing for
transplants, but does advise modifications for initial tacrolimus
treatment using the CYP3A5 genotype if known (Table 3).ZO
Conclusion
While tacrolimus is a standard immunosuppressant for
nearly all kidney transplant recipients, it has a narrow therapeutic index, high inter-patient variability, significant drug
interactions, and major risks for severe adverse events including rejection and nephrotoxicity. The presence of genetic
polymorphisms in the CYP3AS enzyme can affect tacrolimus
metabolism and, consequently, blood levels, contributing to
patient variability in response. Determining the genotype of
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Table 3. Dosing recommendations for tacrolimus based on CYP3A5 genotype.20
CYP3A5
phenotype a

Implications for tacrolimus
pharmacologic measures

Therapeutic recommendationsh

Classification of
recommendationsc

Extensive
Metabolizer
(CYP3A5 expresser)

Lower dose-adjusted trough concentrations of tacro!imus, and decreased chance of achieving target
tacrolimus concentrations.

Increase starting dose to 1.5 to 2
Strong
times of the recommended starting
dose.d Total starting dose should not
exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose
adjustments.

Intermediate
Metabolizer
(CYP3AS expresser)

Lower dose-adjusted trough concentrations of tacrolimus, and decreased chance of achieving target
tacrolimus concentrations.

Increase starting dose to 1.5 to 2 times Strong
of the recommended starting
dose.:_ Total starting dose should not
exceed 0.3 mg/kg/day. Use therapeu!tic drug monitoring to guide dose adpustments.

Poor Metabolizer
(CYP3AS nonexpresser)

Higher ("normal") dose-adjusted
trough concentrations of tacrolimus, and increased chance of
achieving target tacrolimus concentrations.

Initiate therapy with standard recommended dose. Use therapeutic
drug monitoring to guide dose adjustments.

Strong

aTypically with other CYP enzymes, an extensive metabolizer would be classified as a "normal" metabolizer, and therefore,
the drug dose would not change based on the patient's genotype. However, in the case oftacrolimus and the CYP3A5 genotype, a CYP3AS expresser (i.e., CYP3A5 extensive metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3AS non-expresser (i.e., poor metabolizer) would require the standard recommended
starting dose.
bThis recommendation includes the use oftacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients,
and liver transplant patients where the donor and recipient genotypes are identical.
0 Rating scheme is described in Supplementary Data online.
dfurther dose adjustments or selection of alternative therapy may be necessary because of other clinical factors (e.g., medication interactions or hepatic function).
Reproduced with permission off ohn Wiley and Sons, Inc., from Birdwell et al., Clin Pharmacol Ther. 2015. Jul; 98(1):21-24.
©2015 American Society for Clinical Pharmacology and Therapeutics.
CYP3AS can allow for initial dose adjustments, and improve
the ability to reach and maintain target tacrolimus concentrations. Further trials considering CYP3AS polymorphisms
are needed to determine whether this genotype dosing improves clinical outcomes such as reducing rejection, toxicity
and drug interactions before testing can be recommended.
Additionally, other dynamics contribute to the interindividual differences to drug response, and CYP3A5 genotype alone cannot fully account for variability in tacrolimus
metabolism. Despite these limitations, CYP3AS genotyping
has the potential to improve post-transplant therapy outcomes and help prevent the occurrence of serious adverse
effects.
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